Heart Failure
Vectorious Medical Technologies Begins the VECTOR-HF II Study of its Implantable In-Heart Sensor for Left Atrial Pressure-Guided Patient Self-Management of Heart Failure
Vectorious Medical Technologies advises for the first time, heart failure patients can have full visibility of their hearts’ LA pressure and self-adjust their medication to stop further deterioration and avoid hospitalizations.
VUNO Med®-DeepECG™ Designated as Breakthrough Device
VUNO Chairman Lee Yeha said, "VUNO will continue to deliver the value of AI to even more beneficiaries through a wide range of biosignal initiatives, including the use of ECG data with its significant potential for providing clues to serious heart-related diseases."
First Japanese Patients Randomized In Corvia Medical’s REDUCE LAP-HF II Global Clinical Trial For Heart Failure
REDUCE LAP-HF II Global Clinical Trial is a prospective, double-blind, sham-controlled clinical trial randomizing 608 HFpEF and HFmrEF patients in the US, EU, Australia, Japan and Canada.
